Automated Prostate Cancer Detection Using T2-weighted and High-b-value Diffusion-weighted Magnetic Resonance Imaging
Overview
Authors
Affiliations
Purpose: The authors propose a computer-aided diagnosis (CAD) system for prostate cancer to aid in improving the accuracy, reproducibility, and standardization of multiparametric magnetic resonance imaging (MRI).
Methods: The proposed system utilizes two MRI sequences [T2-weighted MRI and high-b-value (b = 2000 s/mm(2)) diffusion-weighted imaging (DWI)] and texture features based on local binary patterns. A three-stage feature selection method is employed to provide the most discriminative features. The authors included a total of 244 patients. Training the CAD system on 108 patients (78 MR-positive prostate cancers and 105 benign MR-positive lesions), two validation studies were retrospectively performed on 136 patients (68 MR-positive prostate cancers, 111 benign MR-positive lesions, and 117 MR-negative benign lesions).
Results: In distinguishing cancer from MR-positive benign lesions, an area under receiver operating characteristic curve (AUC) of 0.83 [95% confidence interval (CI): 0.76-0.89] was achieved. For cancer vs MR-positive or MR-negative benign lesions, the authors obtained an AUC of 0.89 AUC (95% CI: 0.84-0.93). The performance of the CAD system was not dependent on the specific regions of the prostate, e.g., a peripheral zone or transition zone. Moreover, the CAD system outperformed other combinations of MRI sequences: T2W MRI, high-b-value DWI, and the standard apparent diffusion coefficient (ADC) map of DWI.
Conclusions: The novel CAD system is able to detect the discriminative texture features for cancer detection and localization and is a promising tool for improving the quality and efficiency of prostate cancer diagnosis.
Tang G, Zhou H, Zeng C, Jiang Y, Li Y, Hou L Epilepsia Open. 2024; 9(4):1515-1525.
PMID: 38943548 PMC: 11296122. DOI: 10.1002/epi4.12990.
Iruvuri A, Miryala G, Khan Y, Ramalingam N, Sevugaperumal B, Soman M Cureus. 2024; 15(12):e50292.
PMID: 38205468 PMC: 10776831. DOI: 10.7759/cureus.50292.
Clinical-Genomic Risk Group Classification of Suspicious Lesions on Prostate Multiparametric-MRI.
Stoyanova R, Zavala-Romero O, Kwon D, Breto A, Xu I, Algohary A Cancers (Basel). 2023; 15(21).
PMID: 37958414 PMC: 10647832. DOI: 10.3390/cancers15215240.
Zeevi T, Leapman M, Sprenkle P, Venkataraman R, Staib L, Onofrey J IEEE Trans Biomed Eng. 2023; 71(3):1084-1091.
PMID: 37874731 PMC: 10901528. DOI: 10.1109/TBME.2023.3326799.
Gibala S, Obuchowicz R, Lasek J, Schneider Z, Piorkowski A, Pociask E J Clin Med. 2023; 12(8).
PMID: 37109173 PMC: 10146387. DOI: 10.3390/jcm12082836.